Active substance
Carbidopa
- US FDA 8
- US price lines 8
- Safety 12
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LODOSYN | 25MG | tablet · oral | ATON | Prescription | 25 Apr 1977 |
| CARBIDOPA | 25MG | tablet · oral | EDENBRIDGE PHARMS | Prescription | 17 Feb 2016 |
| CARBIDOPA | 25MG | tablet · oral | NOVEL LABS INC | Prescription | 20 Oct 2017 |
| CARBIDOPA | 25MG | tablet · oral | ZYDUS PHARMS | Prescription | 7 May 2018 |
| CARBIDOPA | 25MG | tablet · oral | AUROBINDO PHARMA | Prescription | 21 Oct 2019 |
| CARBIDOPA | 25MG | tablet · oral | REGCON HOLDINGS | Prescription | 11 Dec 2023 |
| CARBIDOPA | 25MG | tablet · oral | ANI PHARMS | Discontinued | 10 Mar 2014 |
| CARBIDOPA | 25MG | tablet · oral | ALVOGEN | Discontinued | 8 Jan 2016 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CARBIDOPA 25 MG TABLET | $0.53596 | per EA | 23 Sep 2026 |
| US NADAC | CARBIDOPA-LEVO 25-100 MG ODT | $0.68655 | per EA | 23 Sep 2026 |
| US NADAC | CARBIDOPA-LEVO ER 23.75-95 CAP | $3.15323 | per EA | 23 Sep 2026 |
| US NADAC | CARBIDOPA-LEVO ER 25-100 TAB | $0.11014 | per EA | 23 Sep 2026 |
| US NADAC | CARBIDOPA-LEVO ER 36.25-145 CP | $3.3941 | per EA | 23 Sep 2026 |
| US NADAC | CARBIDOPA-LEVO ER 48.75-195 CP | $3.18794 | per EA | 23 Sep 2026 |
| US NADAC | CARBIDOPA-LEVO ER 50-200 TAB | $0.17959 | per EA | 23 Sep 2026 |
| US NADAC | CARBIDOPA-LEVO ER 61.25-245 CP | $3.92786 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 15 May 2026 CREXONT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 DHIVY — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 DUOPA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 RYTARY — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 SINEMET — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 SINEMET CR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 STALEVO 100 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 STALEVO 125 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 STALEVO 150 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 STALEVO 200 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 STALEVO 50 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 Mar 2026 STALEVO 75 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Carbidopa
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.